Glenmark launches Bumetanide Injection in SingleDose Vials and Multi-Dose Vials
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
According to IQVIA sales data for the 12-month period ending November 2022, the Bumex Injection, 0.25 mg/mL market achieved annual sales of approximately $16.5 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Buzzing :
Greece in crisisTravel & Budget & EuropeSaaS $ Email MarketingHarnautBlacklisting Policy 2Question Paper Leak 2A big moment for small armsAI in Financial Markets: How Technology is Changing Investing'India's size and diversity make it a powerful innovation engine'Datanomics: Housing, gold loans drive household debt to a decade highSamrat ChoudharyEl Nino
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 10 2023 | 9:05 AM IST